SOS1
Ras/Rac guanine nucleotide exchange factor 1
All Product Categories
-
SOS1 Related Products (89)
Related Products (89)
-
DCAI
0 ImagesCat. No.: HY-118692CAS No.: 299165-92-7DCAI is a KRas inhibitor with a Kd value of 1.1 mM. DCAI directly binds to the Ras protein and competitively inhibits SOS-mediated nucleotide release (IC50 = 155 μM) and exchange reaction (IC50 = 342 μM). DCAI binds to the pocket at the Ras-SOS interface and blocks the formation of the Ras-SOS complex intermediate by impeding salt bridge formation through steric hindrance and the induction of Ras conformational changes. DCAI is used in the study of wild-type and mutant Ras tumors.
-
E8431
0 ImagesCat. No.: HY-180801CAS No.: 2419580-01-9E8431 is a DCSTAMP antagonist with an IC50 value of 775.8 nM for osteoclastogenesis. E8431 selectively binds to the endoplasmic reticulum domain of DCSTAMP, disrupts its interaction with RAP1B, and inhibits downstream cytoskeleton rearrangement mediated by the RAP1-RAC1 signaling pathway, thereby impeding osteoclast precursor fusion, suppressing bone resorption, and stimulating PDGFBB secretion to promote osteogenesis and angiogenesis. E8431 can be used in the research of osteoporosis.
-
(S)-BAY-293
0 ImagesCat. No.: HY-114398ACAS No.: 2244904-69-4(S)-BAY-293 is a negative control of BAY 293. BAY 293 is a potent KRAS-SOS1 interaction inhibitor.
-
SOS1-IN-8
0 ImagesCat. No.: HY-144212CAS No.: 2759387-92-1SOS1-IN-8 is a potent SOS1 inhibitor with IC50s of 11.6 and 40.7 nM for SOS1-G12D and SOS1-G12V, respectively (WO2022017339A1, compound 2).
-
SOS1-IN-7
0 ImagesCat. No.: HY-144211CAS No.: 2755415-30-4SOS1-IN-7 (compound 18-p1) is a potent SOS1 inhibitor with IC50s of 20 and 67 nM for SOS1-G12D and SOS1-G12V, respectively.
-
SOS1-IN-25
0 ImagesCat. No.: HY-179443CAS No.: 3092446-09-5
-
SOS1-IN-19
0 ImagesCat. No.: HY-176170SOS1-IN-19 (Compound 10i) is a potent inhibitor of SOS1 (Son of Sevenless 1) with an IC50 value of 165.2 nM. SOS1-IN-19 blocks KRAS activation by preventing GDP/GTP exchange in KRAS signaling pathway. SOS1-IN-19 is promising for research of KRAS-driven cancers (e.g., NSCLC and colorectal cancer).
-
PROTAC SOS1 degrader-5
0 ImagesCat. No.: HY-161173CAS No.: 2836273-61-9PROTAC SOS1 degrader-5 is a potent SOS1 PROTAC degrader with a DC50 value of 13 nM. PROTAC SOS1 degrader-5 induces CRBN-dependent ubiquitination and degradation of SOS1 protein, inhibits the proliferation of KRASG12C-mutated cancer cells, and suppresses tumor growth in xenograft models. PROTAC SOS1 degrader-5 can be used in studies related to KRASG12C-mutated non-small cell lung cancer.
-
SOS1 Ligand intermediate-4
0 ImagesCat. No.: HY-161635CAS No.: 3036155-94-6SOS1 Ligand intermediate-4 is a ligand of SOS1, used for the synthesis of PROTAC SOS1 degrader (HY-161634).
-
RAS activator compound 1
0 ImagesRAS activator compound 1 (Compound 7c) is a RAS activator targeting the guanine nucleotide exchange factor (GEF) son of sevenless homologue 1 (SOS1). RAS activator compound 1 can activate the nucleotide exchange process and increase levels of active RAS-GTP in HeLa cells. RAS activator compound 1 can be used for research of RAS-driven tumor.
-
SOS1-IN-3
0 ImagesCat. No.: HY-145046CAS No.: 2359689-76-0SOS1-IN-3 is a potent SOS1 (son of sevenless homolog 1) inhibitor with an IC50 of 5 nM. SOS1-IN-3 has anticancer effects (WO2019122129A1; compound I-1).
-
SOS1-IN-27
0 ImagesCat. No.: HY-184423SOS1-IN-27 is a potent, selective allosteric SOS1 inhibitor with a KD of 14 nM and SOS1-KRAS binding IC50 of 1.6 nM. SOS1-IN-27 disrupts SOS1-KRAS interaction, inhibits MAPK/PI3K signaling, induces G1 arrest and tumor cell apoptosis. SOS1-IN-27 serves as a valuable tool compound for pan-KRAS-driven colorectal cancer studies.
-
SOS1 activator 2
0 ImagesCat. No.: HY-167768CAS No.: 2245237-54-9
-
SOS1-IN-12
0 ImagesSOS1-IN-12 is a potent son of sevenless homolog 1 (SOS1) inhibitor with a Ki of 0.11 nM for SOS1 and an IC50 of 47 nM for pERK. SOS1-IN-13 can be used for researching anticancer.
-
SOS1-IN-17
0 ImagesCat. No.: HY-168716SOS1-IN-17 (Compound 8d) is an orally active inhibitor for SOS1-KRASG12C interaction with an IC50 of 5.1 nM. SOS1-IN-17 inhibits ERK phosphorylation in DLD-1 cell with an IC50 of 18 nM. SOS1-IN-17 exhibits anti-proliferative activity in KRASG12C mutated Mia-Paca-2 cell with an IC50 of 0.11 μM. SOS1-IN-17 exhibits antitumor efficacy against pancreatic cancer in mouse model.
-
LHF418
0 ImagesCat. No.: HY-161450LHF418 is a SOS1 PROTAC degrader that induces the degradation of the target protein SOS1 by recruiting cereblon. LHF418 promotes the formation of the SOS1-PROTAC-CRBN ternary complex and induces SOS1 degradation in a cereblon- and proteasome-dependent manner. LHF418 inhibits EGF-induced ERK1/2 phosphorylation and the clonogenic growth of KRAS-mutant cancer cells. LHF418 can be used in studies related to SOS1-targeted protein degradation and KRAS-driven tumors.
-
SOS1-IN-10
0 ImagesCat. No.: HY-144213CAS No.: 2758690-15-0SOS1-IN-10 is a potent SOS1 inhibitor with an IC50 of 13 nM for KRAS G12C-SOS1 (WO2022017519A1, compound 8).
-
SOS1/KRAS-IN-2
0 ImagesCat. No.: HY-181807SOS1/KRAS-IN-2 (Compound 20) is a SOS1::KRASG12C protein-protein interaction inhibitor with a IC50 of 4.11 nM. SOS1/KRAS-IN-2 blocks the interaction between SOS1 and KRASG12C. SOS1/KRAS-IN-2 induces cell Apoptosis. SOS1/KRAS-IN-2 exhibits anticancer activity against colorectal cancer and tongue squamous cell carcinoma.
